NanoViricides

Sometimes you have to read between the lines in order to recognize an emerging opportunity with enough clarity to make a calculated speculation. It is contained in the press release issued this morning by NanoViricides. More comment after the short text of the release (emphasis added):
--------------------------------------------------------------------------------------------

NanoViricides, Inc. President Invited to Speak About Rapid Drug Development

Dr. Diwan to speak about rapid drug development enabled by nanoviricides™ technology at the NanoBusiness2009 Conference


On Tuesday September 8, 2009, 7:00 am EDT

WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced today that Anil Diwan, PhD, President of the Company has been asked to present a talk at NanoBusiness2009 - the 8th annual NanoBusiness Conference.

Dr. Diwan will speak about the nanoviricides™ drug pipeline, including Influenza (FluCide™), HIV (HIVCide™), antiviral eye-drops (EKCCide™) and the newly initiated Herpes “cold sores” and genital herpes preclinical stage program. He will speak about how the nanoviricides technology platform has enabled rapid drug development against a number of diseases caused by many different viruses. Dr. Diwan will speak in the session entitled “New Pharmaceutical Compounds Based on Soft Nanotechnology: Novel Classes of Therapeutics” on Wednesday, September 9.

The Conference is being held at the McCormick Place, Chicago, IL.

About NanoBusiness2009

This is the 8th annual conference on the business of nanotechnology organized by the NanoBusiness Alliance. The NanoBusiness Alliance mission is to create a collective voice for the advancing nanotechnology industry and develop a range of initiatives to support the nanotechnology business community.

--------------------------------------------------------------------------------------------
First of all, let's take a look at a short biography of Dr. Diwan (emphasis added):

Anil R. Diwan, PhD
Chairman and President

Inventor of TheraCour technology that enables NanoViricides drugs.

Dr. Diwan has extensive product development experience while raising financing from collaborations, SBIR grants, other revenues. He has extensive experience in a number of bio-pharmaceutical, biosciences, and biomedical fields and technologies that leads to his novel, integrative approach in solving problems with low costs, high innovation, and world-leading feature sets. Dr. Diwan is the inventor, developer, and principal investor of TheraCour technologies. The nanomaterials based on these technologies form the basis of nanoviricides drugs.

Anil holds a US patent on his older polymeric micelle technologies, with his colleagues at University of Massachusetts. He has continued to work further in the field, to develop nanomaterials that are capable of multi-specific multi-targeting of viruses, and at the same time capable of encapsulating active pharmaceutical ingredients (API) in industry-leading payload capacities. This new work has resulted in nanomaterials called "TheraCour" (therapeutic courier), and the underlying technology is subject of a new patent application. Multi-targeting allows binding to the virus particle like a Velcro tape, and Multi-specificity allows highly selective binding to a specific type of virus. The encapsulated API can get injected into the virus particle.

Cutting to the chase, Dr. Diwan is the inventor of the nanomaterial that destroys viruses and we are the shareholders of the company that has exclusive rights to develop and market the technology. Dr. Diwan is talking in Chicago on Wednesday to update NNVC's pipeline.....and rapid drug development platform.

We know that there are multiple ongoing testing protocols across a wide selection of targeted viruses and being performed by private labs, big pharma, educational institutions, the CDC and the NIH. What we don't know yet is how well those tests are going and what if any findings are imminent.

What are the chances that Dr Diwan's scheduled appearance has some very good news attached to it?

This may end up being a non-event with no significant news coming out of it. Or it might be the polar opposite, with ground-breaking news making headlines across the medical universe. My best guess? Something in-between these last two outcomes. Just where it lands on the continuum between the two, that is what speculation is all about.


A